Actos® Bladder Cancer
The U.S. Food and Drug Administration (FDA) warns that use of the diabetes medication ActosÂ® (pioglitazone) for more than one year has been associated with a 40 percent increase in risk for bladder cancer. The FDA urges patients who have taken Actos to contact a medical professional immediately if they experience any of the following symptoms:
- Blood or red color in urine
- Urgent need to urinate or pain while urinating
- Pain in back or lower abdomen
Information about the risk of bladder cancer associated with Actos has been added to the "warnings and precautions"section of the label for pioglitazone-containing medicines as well as the patient medication guide.
In April 2014, a jury found that the manufacturers of Actos, Takeda Pharmaceutical Company Limited and Eli Lilly & Company, hid the cancer risks of the drug. The two companies were ordered to pay a combined $9 Billion in punitive damagesâthe seventh-largest jury award in U.S. history.
Different Products, Same Risk
The active ingredient in Actos (pioglitazone) is also sold in combination with metformin (Actoplus MetÂ®, Actoplus Met XRÂ®) and glimepiride (DuetactÂ®). From January 2010 through October 2010, approximately 2.3 million patients filled prescriptions for a pioglitazone-containing product from outpatient retail pharmacies.
Get the Help You Deserve
If you or someone you love has taken a diabetes medication containing pioglitazone and was diagnosed with bladder cancer, you may be entitled to compensation. Contact us immediately for a free and confidential case evaluation, and get the help you deserve.
Never stop taking any medication without first consulting your doctor. ActosÂ®, Actoplus MetÂ®, Actoplus Met XRÂ®, and DuetactÂ® are registered trademarks of Takeda Pharmaceutical Company Limited and are used here only for the purpose of identifying the products in question. This law firm is not associated with, sponsored by, or affiliated with the U.S. Food and Drug Administration, Takeda Pharmaceutical Company Limited, Eli Lilly & Company, or Bloomberg.